Original language | English (US) |
---|---|
Pages (from-to) | 245-246 |
Number of pages | 2 |
Journal | JACC: Heart Failure |
Volume | 8 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2020 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: JACC: Heart Failure, Vol. 8, No. 3, 03.2020, p. 245-246.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Reply
T2 - Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction
AU - Chandra, Alvin
AU - Vaduganathan, Muthiah
AU - Lewis, Eldrin F.
AU - Claggett, Brian
AU - McMurray, John J.V.
AU - Solomon, Scott D.
N1 - Funding Information: Please note: This study was supported by Novartis. Novartis participated in the design and conduct of the PARAGON-HF trial; collection, management, and interpretation of the data; and reviewed and commented on the manuscript prior to submission for publication. The sponsor otherwise had no role in the analysis of the data, preparation of this manuscript or the decision to submit this manuscript for publication. Dr. Vaduganathan is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (National Institutes of Health/National Center for Advancing Translational Sciences Award UL 1TR002541); and has served on the advisory board for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, and Relypsa. Dr. Lewis has received institutional research grants from Novartis, Amgen, and Sanofi in order to conduct clinical trials; and served as a consultant for Novartis and Amgen. Dr. Claggett has received consulting fees from AOBiome, Biogen, Boehringer Ingelheim, Corvia Medical, Gilead Sciences, and MyoKardia. Dr. McMurray has received fees for serving on a steering committee (paid to Glasgow University) from Bayer, DalCor Pharmaceuticals, and Bristol-Myers Squibb; fees for serving on a steering committee (paid to Glasgow University); fees for serving as chair of an endpoint committee (paid to Glasgow University); travel support (paid to Glasgow University) and fees for serving on a steering committee (paid to Glasgow University); travel support (paid to Glasgow University) from Amgen, Oxford University–Bayer, and AbbVie; fees for serving as principal investigator (paid to Glasgow University); travel support (paid to Glasgow University) from Theracos; fees for serving on a data and safety monitoring board (paid to Glasgow University) from Pfizer and Merck; fees for serving as principal investigator and co-principal investigator (paid to Glasgow University); travel support (paid to Glasgow University) from AstraZeneca; fees for serving as co-principal investigator (paid to Glasgow University); fees for serving on a steering committee (paid to Glasgow University); travel support (paid to Glasgow University) from GlaxoSmithKline; fees for serving on a steering committee (paid to Glasgow University); fees for serving on an endpoint adjudication committee (paid to Glasgow University); travel support (paid to Glasgow University) from Vifor Pharma–Fresenius; fees for serving on an executive committee (paid to Glasgow University); fee for serving as co-principal investigator (paid to Glasgow University); fees for serving on an executive committee and steering committee (paid to Glasgow University); fees for serving on an advisory board (paid to Glasgow University); travel support (paid to Glasgow University) from Novartis; fees for serving on a steering committee (paid to Glasgow University); fees for serving as chair of an end-point committee (paid to Glasgow University); and travel support (paid to Glasgow University) from Cardiorentis. Dr. Solomon has received research grant support from Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol-Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lone Star Heart, Mesoblast, MyoKardia, National Institutes of Health/National Heart, Lung, and Blood Institute, Novartis, Sanofi Pasteur, and Theracos; and has served as a consultant for Akros, Alnylam, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Cardior, Corvia, Cytokinetics, Gilead, GlaxoSmithKline, Ironwood, Merck, Novartis, Roche, Takeda, Theracos, Quantum Genetics, Cardurion, AOBiome, Janssen, and Cardiac Dimensions. Dr. Chandra has reported that he has no relationships relevant to the contents of this paper to disclose. Funding Information: Please note: This study was supported by Novartis. Novartis participated in the design and conduct of the PARAGON-HF trial; collection, management, and interpretation of the data; and reviewed and commented on the manuscript prior to submission for publication. The sponsor otherwise had no role in the analysis of the data, preparation of this manuscript or the decision to submit this manuscript for publication. Dr. Vaduganathan is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (National Institutes of Health/National Center for Advancing Translational Sciences Award UL 1TR002541); and has served on the advisory board for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, and Relypsa. Dr. Lewis has received institutional research grants from Novartis, Amgen, and Sanofi in order to conduct clinical trials; and served as a consultant for Novartis and Amgen. Dr. Claggett has received consulting fees from AOBiome, Biogen, Boehringer Ingelheim, Corvia Medical, Gilead Sciences, and MyoKardia. Dr. McMurray has received fees for serving on a steering committee (paid to Glasgow University) from Bayer, DalCor Pharmaceuticals, and Bristol-Myers Squibb; fees for serving on a steering committee (paid to Glasgow University); fees for serving as chair of an endpoint committee (paid to Glasgow University); travel support (paid to Glasgow University) and fees for serving on a steering committee (paid to Glasgow University); travel support (paid to Glasgow University) from Amgen, Oxford University?Bayer, and AbbVie; fees for serving as principal investigator (paid to Glasgow University); travel support (paid to Glasgow University) from Theracos; fees for serving on a data and safety monitoring board (paid to Glasgow University) from Pfizer and Merck; fees for serving as principal investigator and co-principal investigator (paid to Glasgow University); travel support (paid to Glasgow University) from AstraZeneca; fees for serving as co-principal investigator (paid to Glasgow University); fees for serving on a steering committee (paid to Glasgow University); travel support (paid to Glasgow University) from GlaxoSmithKline; fees for serving on a steering committee (paid to Glasgow University); fees for serving on an endpoint adjudication committee (paid to Glasgow University); travel support (paid to Glasgow University) from Vifor Pharma?Fresenius; fees for serving on an executive committee (paid to Glasgow University); fee for serving as co-principal investigator (paid to Glasgow University); fees for serving on an executive committee and steering committee (paid to Glasgow University); fees for serving on an advisory board (paid to Glasgow University); travel support (paid to Glasgow University) from Novartis; fees for serving on a steering committee (paid to Glasgow University); fees for serving as chair of an end-point committee (paid to Glasgow University); and travel support (paid to Glasgow University) from Cardiorentis. Dr. Solomon has received research grant support from Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol-Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lone Star Heart, Mesoblast, MyoKardia, National Institutes of Health/National Heart, Lung, and Blood Institute, Novartis, Sanofi Pasteur, and Theracos; and has served as a consultant for Akros, Alnylam, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Cardior, Corvia, Cytokinetics, Gilead, GlaxoSmithKline, Ironwood, Merck, Novartis, Roche, Takeda, Theracos, Quantum Genetics, Cardurion, AOBiome, Janssen, and Cardiac Dimensions. Dr. Chandra has reported that he has no relationships relevant to the contents of this paper to disclose.
PY - 2020/3
Y1 - 2020/3
UR - http://www.scopus.com/inward/record.url?scp=85079388587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079388587&partnerID=8YFLogxK
U2 - 10.1016/j.jchf.2019.12.002
DO - 10.1016/j.jchf.2019.12.002
M3 - Letter
C2 - 32131029
AN - SCOPUS:85079388587
SN - 2213-1779
VL - 8
SP - 245
EP - 246
JO - JACC: Heart Failure
JF - JACC: Heart Failure
IS - 3
ER -